Pharmacoepidemiology resources in Ireland-an introduction to pharmacy claims data. by Sinnott, Sarah-Jo et al.
Sinnott, SJ; Bennett, K; Cahir, C (2017) Pharmacoepidemiology re-
sources in Ireland-an introduction to pharmacy claims data. Euro-
pean journal of clinical pharmacology. ISSN 0031-6970 DOI: https://doi.org/10.1007/s00228-
017-2310-7
Downloaded from: http://researchonline.lshtm.ac.uk/4258888/
DOI: 10.1007/s00228-017-2310-7
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
PHARMACOEPIDEMIOLOGYAND PRESCRIPTION
Pharmacoepidemiology resources in Ireland—an introduction
to pharmacy claims data
Sarah-Jo Sinnott1 & Kathleen Bennett2 & Caitriona Cahir2
Received: 9 April 2017 /Accepted: 21 July 2017 /Published online: 17 August 2017
# The Author(s) 2017, corrected publication October/2017. This article is an open access publication
Abstract
Introduction Administrative health data, such as pharmacy
claims data, present a valuable resource for conducting
pharmacoepidemiological and health services research.
Often, data are available for whole populations allowing pop-
ulation level analyses. Moreover, their routine collection en-
sures that the data reflect health care utilisation in the real-
world setting compared to data collected in clinical trials.
Setting and methods The Irish Health Service Executive-
Primary Care Reimbursement Service (HSE-PCRS) commu-
nity pharmacy claims database is described. The availability
of demographic variables and drug-related information is
discussed. The strengths and limitations associated using this
database for conducting research are presented, in particular,
internal and external validity. Examples of recently conducted
research using the HSE-PCRS pharmacy claims database are
used to illustrate the breadth of its use.
Results and conclusions The HSE-PCRS national pharmacy
claims database is a large, high-quality, valid and accurate data
source for measuring drug exposure in specific populations in
Ireland. The main limitation is the lack of generalisability for
those aged <70 years and the lack of information on indication
or outcome.
Keywords Database . Pharmacoepidemiology . Drug
utilisation . Claims data
Introduction
Pharmacy claims data offer substantial potential for study-
ing the effects of drugs in large populations, and in spe-
cific populations such as the elderly which are often not
represented in clinical trials [1]. The Health Service
Executive-Primary Care Reimbursement Service (HSE-
PCRS) pharmacy claims database in Ireland is widely
used in pharmacoepidemiology research, drug utilisation
research and health services research.
The aims of this review are to (i) provide an overview of the
health system in Ireland, setting the context for the use of the
national HSE-PCRS pharmacy claims database in health care
provision; (ii) describe the HSE-PCRS database and (iii) de-
scribe the validity of the database, including both internal and
external validity. Lastly, examples of research conducted
using the database are provided.
Description of the health system and reimbursement
of medicines
Ireland is the only European country that does not provide
universal access to primary health care [2]. Instead, the Irish
healthcare system, which is predominantly tax funded,
operates on a complex two-tiered basis [3]. Across these pub-
lic and private tiers, the majority of pharmaceutical expendi-
ture is funded through the National Shared Services HSE-
PCRS. Three principal community drug schemes exist under
this system: (i) General Medical Services (GMS) scheme, (ii)
Drug Payment (DP) scheme and (iii) Long-Term Illness (LTI)
scheme. Altogether, the community drug schemes account for
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approximately 82% of total public expenditure on the acqui-
sition cost of pharmaceuticals prescribed by GPs [4]. Other
smaller specific schemes also exist, for example the metha-
done treatment scheme for opioid dependence and a high-
technology drugs scheme which provides access to high-cost
innovative treatments, e.g. immunologics and cancer treat-
ments, but these not discussed further here [4].
General Medical Services scheme
In 2015, almost 40% of the population (1.7 million people)
were in receipt of public health insurance, or covered by the
GMS scheme (known as medical card holders) [5]. The GMS
scheme entitles the individual to primary care services and
hospital services free at the point of access. The exception to
this is that prescription medications are subject to a flat
copayment. The current copayment (as of March 2017) is
€2.50 per item (capped at €25 per month per household) and
€2.00 per item for those aged over 70 years (capped at €20 per
month). Copayment exemptions are extended to children in
the care of the HSE, for example in foster care, and people
living in emergency reception accommodation under the Irish
Refugee Protection Programme. The supply of methadone for
opioid dependence is also not subject to copayment.
Qualification for the GMS scheme is on the basis of income-
related means-testing [4]. Automatic entitlement for those
aged ≥70 years occurred between July 2001 and December
2008; however, since January 2009, means-testing was intro-
duced for those aged ≥70 years but with a higher income
threshold than those aged ≥66 years and those aged <66 years.
Discretionary medical cards may be awarded in certain cases,
for example at diagnosis of cancer [4].
Drug Payment scheme
The remainder of the population not covered by the GMS
scheme are referred to as being in the “private” tier.
Although hospital services are free to all individuals in
Ireland, a proportion (approximately 46% in 2015) choose to
purchase private health insurance; the main advantage of
which is quicker access to secondary and tertiary specialist
services [3, 6]. For the most part, private health insurance does
not cover primary care services; thus, out-of-pocket payments
for general practitioner (GP) visits are standard practice.
Individuals in the private health care system can receive
government-subsidised access to prescription medications
through the DP scheme. Under the DP scheme, an individual
or a family is responsible for paying up to €144 per month for
their medications. Once this limit is reached, the individual or
family incurs no further cost for the duration of the month [4].
In 2014, 29% of the population accessed medication under
this scheme [4].
Long-Term Illness scheme
The LTI scheme is awarded, independently of income, to in-
dividuals with one of 16 chronic illnesses, for example diabe-
tes mellitus or epilepsy. Individuals in receipt of care on this
scheme, approximately 3% of the population, are provided
with prescription medicines without any copayment.
However, individuals are responsible for GP consultation fees
[4].
Description of the database
Community pharmacists dispensing medications on the main
drug schemes submit their claims every month to the HSE-
PCRS for reimbursement. The vast majority do so electroni-
cally. The HSE-PCRS database thus holds data on every pre-
scription filled in Ireland in the community on the GMS
scheme and the LTI scheme. However, data for medications
dispensed on the DP scheme are incomplete because medica-
tions are paid for in full by the individual/family up to the
monthly threshold. Hence, there is no requirement to submit
a claim to the HSE-PCRS for medications already paid for by
the individual. Drugs administered in hospital are not avail-
able in this database. However, it is possible to explore in-
hospital-initiated therapies in GMS patients only by examin-
ing claims on the “hospital emergency scheme”. This is a
further community drug scheme available to GMS patients
that provides 7 days’ supply of medication on foot of a hospi-
tal prescription, before the prescription must be written by the
GP.
Drug data
For each drug dispensed in Ireland and reimbursed by
HSE-PCRS, data are available in the database for the
date of dispensing, quantity of medication provided,
strength, dosage form, route of administration, ingre-
dient cost, community drug scheme on which drug
was dispensed and dispensing fees to the pharmacist.
Prescriptions are coded using the World Health
Organisat ion Anatomical Therapeut ic Chemical
(WHO-ATC) classification system and corresponding
defined daily dose (DDD) [7]. Data on the dispensing
pharmacy and the prescriber are also collected.
Missing data are negligible for all medication-related
fields.
Demographic data
Information on age and gender at the individual level
are avai lable in the database , wi th negl ig ible
missingness. Information on the HSE region and local
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health office for each patient is also available.
Unfortunately, clinical data and data on lifestyle behav-
iours are not available in this database.
Validation studies
Internal validity
Pharmacy claims databases are thought to be highly accurate
because the data collected must be complete, correct and up-
to-date for reimbursement purposes [1]. In a study of 97 patients
in two Irish hospitals, it was found that the HSE-PCRS database
was the most accurate method of medicine reconciliation rela-
tive to GP records and records from individual community phar-
macies [8]. Additionally, the HSE-PCRS database has been
found to be more accurate and complete than patient self-report,
perhaps due to issues with patient recall, in a study of 2641
patients aged over 50 years. [8, 9].
Furthermore, prior research indicates an association
between drug exposure measured through dispensed
drug records and clinical outcomes [10, 11]. Thus,
pharmacoepidemiological studies using pharmacy
claims data can reasonably attempt to establish associ-
ations between causes (medications) and outcomes
(side effects or medication effectiveness). One limita-
tion of HSE-PCRS data for assessing exposure to med-
ications is worth noting. At present, there is no number
of days’ supply or duration of use variable, which is
common in international prescription claims databases
[12]. The date on which a medication is dispensed
along with the quantity provided can be used to calcu-
late duration. In addition, the number of Daily Defined
Doses (DDDs) can be calculated as a proxy for days’
supply by multiplying the strength of the medication
dispensed by the quantity dispensed and then dividing
this number by the DDD. For example, if a person is
dispensed 112 tablets of 500 mg metformin, which has
a DDD of 2000 mg, the person received 28 DDDs [i.e.
(112 × 500) / 2000]. This method has been demon-
strated to have mixed accuracy for several different
medication types [12].
Other limitations are common to all international
databases of prescription claims [1]. For example, in-
formation on medications not reimbursable by the
HSE-PCRS is not available in the database. This is
somewhat ameliorated in the Irish database due to a
comprehensive reimbursable medications list. The rela-
tively low copayment also means that patients on the
GMS scheme will sometimes opt to get a prescription
for an item that can be bought over the counter, if the
copayment is less than the item cost and eligible for
reimbursement. There is no information on the
indication for the medication or on outcomes of any
medications.
External validity
The GMS population is approximately 40% of the population
[4], but those who are socio-economically disadvantaged
and those aged ≥70 years are over-represented; hence,
there may be some limitations as regards generalisability in
pharmacoepidemiological studies [13]. For those aged ≥70 years,
the database is representative of the Irish population at the same
age, attributable to the fact that almost every person aged
≥70 years is eligible for the GMS scheme [14]. As of 2013,
90% of men and 94% of women aged ≥70 years were eligible
[14]. Therefore, studies in those aged ≥70 years have greater
external validity than for other age groups. For example, a study
comparing the prevalence of potentially inappropriate prescrib-
ing in the Republic of Ireland andNorthern Ireland (which is part
of the UK) found that potentially inappropriate prescribing rates
were similar between the two populations, when restricted to
those aged ≥70 years [15].
However, less than 50% of the Irish population aged
<70 years of age are covered by the GMS scheme (Table 1).
The impact of this limitation on generalisability was highlighted
in a study comparing potentially inappropriate prescribing be-
tween the Republic of Ireland and Northern Ireland; differences
in the prevalence of potentially inappropriate prescribing be-
tween the settings were attributed to a larger proportion of so-
cially disadvantaged middle-aged adults in the Irish database
[16]. Additionally, greater proportions of those covered by the
GMS scheme are smokers and female than in the general pop-
ulation [13]. In studies of drug effects, care must be taken to
ensure no prior evidence of confounding or effect modification
Table 1 Proportion of Irish men and women on GMS scheme
Age group (years) % Men % Women
0–15 40.4 39.8
16–24 36.9 43.2
25–34 27.4 32.9
35–44 30.1 33.6
45–54 31.0 31.4
55–64 33.6 35.7
65–69 43.6 55.8
70+ 89.9 93.8
Total 38.3 42.2
Source: Health Service Executive and Central Statistics Office, available
at http://www.cso.ie/en/releasesandpublications/ep/p-wamii/
womenandmeninireland2013/healthlist/health/#d.en.65619
The % column represents the % men/women in the Irish population on
the General Medical Services (GMS) scheme
GMS General Medical Services scheme
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by smoking status. If no confounding or effect modification
exists (In studies of drug effects, care must be taken to ensure
no prior evidence of confounding or effect modification by life-
style factors such as smoking.), one could reasonably assume
that the effects of a drug in this population will be no different to
a general population [13].
Examples of research using the HSE-PCRS database
Chronic disease epidemiology
Methods to calculate burden of disease metrics frequently re-
quire weighting of the data to reflect underlying population
trends that cannot be detected in sample-based surveys or
cohort studies. The HSE-PCRS database allows calculation
(rather than estimation) of disease prevalence in specific pop-
ulations such as those aged ≥70 years and those with specific
diseases. For example, Naughton et al. calculated the preva-
lence of chronic disease in those aged >70 years [17]. Sinnott
et al. calculated the prevalence and incidence of type 2 diabe-
tes mellitus using GMS and LTI data, which when combined,
provide data on every diabetes medication dispensed in
Ireland, thus capturing all treated individuals with diabetes
[18]. A limitation of the data in this respect is that without
codes for diagnosis/indication, some misclassification is pos-
sible, for example women with polycystic ovary syndrome
who are treated with metformin may be included in the diabe-
tes numerator [18].
Health services research
Health services research in Ireland has developed rapidly in
recent years. The availability of the HSE-PCRS database has
enabled the conduct of high-quality drug utilisation research,
research into adherence to medicines and also policy analysis.
Drug utilisation research
Drug utilisation research refers to the study of the use of med-
icines in populations, with special emphasis on the resulting
medical, social and economic consequences [19]. Trends in
the prescribing of (1) psychotropic medicines and antibiotics
in paediatric populations, (2) oral contraceptive use and (3) the
prevalence of polypharmacy (≥5 concurrent prescribed medi-
cations) have all been recently explored using HSE-PCRS
data [20–23]. The effectiveness of randomised interventions
designed to improve the prescribing of (i) antibiotics and (ii)
preventive therapies in cardiovascular disease was evaluated
using data held in the HSE-PCRS database for each GP prac-
tice involved in each of the trials [24, 25]. Such trials are good
examples of how interventional studies in the area of
pharmacoepidemiology/drug utilisation research can be
carried out pragmatically, contingent upon the availability of
an up-to-date claims database and consent of involved parties.
The Health Products Regulatory Authority, the regulatory
agency for medicines and medical devices in Ireland, fre-
quently publishes drug safety warnings [26]. How these warn-
ings affect the prescribing and dispensing of medicines was
analysed using the HSE-PCRS database in 2011, with a sum-
mary finding that inconsistent effects on the use of various
drugs after safety warnings occurs [27]. In contrast, publicity
surrounding clinical trials of hormone replacement therapy
(HRT) in menopausal women was found to have a significant
negative effect on the prescribing of HRT in this patient group
[28].
The availability of the HSE-PCRS database has also facil-
itated research into potentially inappropriate prescribing, and
associated costs [29–31]. Relying on the national nature of the
data, and regional information within the database, Cahir et al.
used the HSE-PCRS database to explore regional variation in
potentially inappropriate prescribing to adults ≥70 years [32].
This study found up to fourfold differences in rates of poten-
tially inappropriate prescribing, but this was mostly insignifi-
cant after adjusting for patient level variables [32].
The practical value of the database in making predictions
for future costs to government has recently been explored. The
demographic structure of Irish society is rapidly changing,
owing mostly to an ageing population [33]. The impact of this
demographic change onmedication costs on the GMS scheme
has been forecast using current HSE-PCRS data and Central
Statistics Office population projections. It is estimated that the
GMS medications bill will rise from €1.3 billion in 2016 to
€1.9 billion in 2026 [34].
Adherence and medication-taking behaviour
Pharmacy claims data offer a useful tool for assessing
medication-taking behaviour in patients with chronic
diseases and are particularly useful for the evaluation
of drugs intended for long-term therapy. Medication-
taking behaviour can be defined in terms of two distinct
variables: (1) adherence which is acting in accordance
with the agreed prescribed interval and dosage of the
treatment and (2) persistence which is continuing the
treatment for the prescribed duration of time [35]. The
HSE-PCRS has been used successfully to describe ad-
herence and persistence to medication, treatment initia-
tion, treatment switching, socio-demographic predictors
and regional variation in medication-taking behaviour
in various chronic diseases and cancers over time
[36–40]. It is important to acknowledge, however, that
adherence and persistence measures based on dispensed
drug data reflect drug availability as opposed to true
exposure.
1452 Eur J Clin Pharmacol (2017) 73:1449–1455
Pharmaceutical policy analysis
After the global economic recession in 2008, several policy
measures were implemented in Ireland to help reduce expen-
diture on publicly reimbursed medications. First, a copayment
on the GMS scheme was introduced in October 2010 at 50c
per prescription item. Using HSE-PCRS data to evaluate the
impact of this policy, Sinnott et al. found that adherence to
less-essential medicines was affected to a greater degree than
adherence to essential medicines. The exception to this pattern
was that adherence to anti-depressant medicines was reduced
substantially after the introduction of the copayment, and its
subsequent increase to €1.50 [41]. Second, reference pricing
and generic substitution were legislated for and introduced on
the community drug schemes in 2013. An assessment of cost
data in the HSE-PCRS database demonstrated substantial sav-
ings of 53% to the exchequer after the introduction of this
policy [42]. In absolute terms, this amounted to €35million
[42]. Current policies such as the administration of the sea-
sonal influenza vaccine through community pharmacies may
be analysable in the future for clinical and cost-effectiveness.
Pharmacoeconomics and health technology assessment
Pharmacoeconomic analyses are used to decide whether the
use of a new drug is likely to represent value for money for
the health care system. Such analyses are generally compara-
tive in nature, requiring information on the costs and effects of
alternative treatments in specific indications, which is a typical
task of a drug utilisation study [43]. Real-world pharmacy
claims data are also helpful in establishing whether evidence
from the highly selected populations in phase III randomised
controlled trials are transferrable to the unselected populations
of everyday clinical practice [44]. The numbers of eligible re-
cipients of new drugs can be calculated from existing pharmacy
claims data to provide an estimate of the likely budget impact
of introducing or reimbursement of these new medicines [18].
Current linkages
The National Cancer Registry Ireland (NCRI), a population-
based cancer registry, has been linked with HSE-PCRS data,
so that detailed information on medication use is available for
those with GMS eligibility and a diagnosis of cancer. This
linked database facilitates detailed and high-quality
pharmacoepidemiological studies of cancer survival with nu-
anced drug exposure data available in combination with com-
prehensive clinical data on type and staging of cancer [45, 46].
A second linkage has been established with The Irish
Longitudinal Study of Ageing (TILDA), a nationally repre-
sentative cohort study of over 8000 adults aged >50 years
[47]. This linkage has permitted the conduct of high-quality
health services research, in particular of potentially
inappropriate prescribing [29, 48]. Linkages have also been
established for hospital [49] and mortality data [50].
Conclusions
The national pharmacy claims database in Ireland is large and
highly accurate. Although it is limited by its generalisability for
those aged less than 70 years, it is almost completely represen-
tative of those aged ≥70 years. This is significant because older
people will make up more than 20% of Ireland’s population by
2040 [33]. Furthermore, older people use themost medications
in the population [51]. Thus, the ability to carry out
pharmacoepidemiological research in this population is of par-
amount importance. For pharmacoepidemiological research
seeking to make associations between drug causes and effects
(side effects, effectiveness), the generalisability to the younger
population is of concern if is of concern if lifestyle factors such
as smoking are confounding variables smoking are confound-
ing variables or effect modifiers of the medication under study.
There are no clinical data in the HSE-PCRS database,
but linkages to other databases are possible where patient
consent is available. The recent legislation for a unique
health identifier in Ireland will assist in the development
of a more complete clinical medication database [52].
Moreover, the current move to incorporate an electronic
health record for each individual presents a new paradigm
for pharmacoepidemiological research in Ireland, within a
framework of anonymity, consent and appropriate gover-
nance [53]. Such linked databases and electronic health
record data present unparalleled opportunities to carry
out much needed medication effectiveness studies to
study rare outcomes, drug safety and drug effects in large
and heterogeneous populations. For example, the number
of heart attacks and strokes in the community reduced by
blood pressure-lowering therapy [54].
The research carried out to date using the HSE-PCRS data-
base has contributed significantly to national policy making.
Global knowledge is amplified through pharmacoepidemiology
studies in cancer, health service research in inappropriate pre-
scribing and pharmacoeconomic analyses [50]. It is now impor-
tant to encourage policy and decision makers to facilitate and
accommodate future linkage of data. This will benefit the con-
duct of pharmacoepidemiological research in Ireland, ultimate-
ly benefitting not only Irish society, but our understanding of
drug effects and safety worldwide.
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